Vonoprazan-Based Dual Therapy Shows Favorable Real-World Outcomes for Helicobacter pylori Eradication

A real-world, single-center observational study published in Gastroenterology Research evaluated 94 adults with Helicobacter pylori infection treated between July 2024 and March 2025. Patients received 14 days of vonoprazan-amoxicillin (VA) dual therapy or proton pump inhibitor-amoxicillin-clarithromycin (PAC) triple therapy. H. pylori eradication, assessed using a repeat rapid urease test, was numerically higher with VA than PAC (93.33% vs. 85.71%), although the difference was not statistically significant.

As second-line therapy, eradication was achieved in 100% of patients who switched from PAC to VA, compared with 33.3% of those who switched from VA to PAC. Patients receiving VA experienced significantly faster symptom resolution (median 3 vs. 5 days; p<0.001), fewer adverse drug reactions (13.33% vs. 28.57%), and a lower incidence of taste disturbances. VA was also associated with…